T he nitrate-nitrite (NO 2
Ϫ )-nitric oxide (NO) pathway 1 is emerging as an important mediator of cell signaling and bioenergetics events, with therapeutic implications in blood flow regulation and tissue responses to hypoxia. 2, 3 Nitroalkene derivatives of unsaturated fatty acids represent the convergence of such NO pathway with lipids 4 because they are formed by NO and NO 2 Ϫ -dependent redox reactions. 1 Thus, they constitute a subset of molecules in the emerging physiological pool of the nitric oxide derived metabolome 5, 6 that control the physiological homeostasis by coordinating adaptive responses. 7, 8 At present, the mechanisms underlying the production of nitrated lipids under biological conditions, specific structural isomer distributions, nitrated fatty acidsusceptible proteome, and detailed biological signaling actions are incompletely characterized. 6 It is agreed that under conditions in which O 2 tension is low (eg, ischemia and anoxia), the balance between peroxyl radical formation and coupling with ⅐ NO 2 shifts toward nitration reactions. 9, 10 Thus, nitroalkenes are significantly increased in the heart after reperfusion in an ischemia/reperfusion injury model, 11 and these species are abundantly generated in the mitochondria of hearts exposed to ischemic preconditioning. 12, 13 Nitroalkenes transduce signaling reactions by covalently modifying nucleophilic protein targets and altering their structure and function. 6 For instance, nitro derivatives of linoleic and oleic (OA-NO 2 ) acids are activators of peroxisome proliferator-activated receptor (PPAR)␥, 14, 15 form covalent adducts with the p65 subunit of nuclear factor B, 16 and activate the Keap1/Nrf2 antioxidant response, reactions that promote adaptive responses in vascular cells. 17, 18 These derivatives of NO-mediated redox reactions represent an inflammatory-resolving adaptive response. 7 In the context of the vasculature, OA-NO 2 inhibits neointimal hyperplasia 19 and exerts vasorelaxation of preconstricted aortic rings. 20 For these reasons, and because of the well-established vasorelaxant properties of pharmacological doses of nitrite, 21 it is plausible to suggest that nitroalkenes will have a significant impact in the regulation of blood pressure and vascular tone.
Herein, we determined whether a nitroalkene derivative ameliorate angiotensin (Ang) II-induced hypertension. As the major component of the renin-angiotensin-aldosterone system, deregulation of Ang II production plays a critical role in the pathogenesis of hypertension. 22 Thus, inhibition of the catalytic activity of the angiotensin converting enzyme (ACE) or competitive inhibition of Ang II type 1 receptor (AT 1 R) ligand binding by angiotensin receptor blockers (ARBs) are 2 prevalent treatment options for hypertension. 23 Also, molecular targets of nitroalkenes, such as PPAR␥ and the AT 1 R reported herein, reflect common signaling targets that influence the progression of hypertension and other cardiovascular and metabolic diseases. 24 
Methods

Ang II-Induced Hypertension Model
Blood pressure (BP) in mice was measured by radiotelemetry. Mice were subjected to subcutaneous implantation of osmotic minipumps for delivery of OA-NO 2 or oleic acid (OA) at a concentration supporting an infusion rate of 5 mg/kg per day, and Ang II was administered at an infusion rate of 500 ng/kg per minute.
In Vivo Infusion for Blood Pressure Tracings and In Vitro Vessel Contraction Analysis
OA or OA-NO 2 and the PPAR␥ inhibitor GW9662 were delivered via the jugular vein. BP recordings were monitored before and after Ang II infusion (10 g/mL, infusion rate: 1 L/min) using a 1.4F microtip catheter sensor inserted into the right carotid artery. Second-order mesenteric arteries from SD rats were mounted onto a myograph. Vessels were pretreated with OA-NO 2 or OA at 2.5 mol/L and 5 mol/L for 10 minutes and then contracted with Ang II, phenylephrine (PE), or endothelin-1 (ET-1), respectively.
Analysis of OA-NO 2 Binding to the AT 1 R
The transalkylation reaction of AT 1 R-bound OA-NO 2 was performed according to the methodology described previously. 13 An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Results
OA-NO 2 Reduces Ang II-Induced Hypertension
To determine whether OA-NO 2 plays a role on Ang IImediated hypertension, we delivered OA-NO 2 (5 mg/kg per day), as well as its nonnitrated counterpart, OA, systemically via osmotic minipumps in C57/BL6 mice. Systemic delivery of OA and OA-NO 2 did not affect baseline systolic or diastolic BP recordings measured by radiotelemetry during the first week of the analysis as compared with polyethylene glycol-treated group that served as vehicle control ( Figure  1A and 1C) . Subsequently, mice were further treated with Ang II, supporting an infusion rate of 500 ng/kg per minute for 2 additional weeks. Under these conditions, OA-NO 2 but not OA significantly reduced Ang II-dependent increases in systolic (Ϸ15 mm Hg reduction) and diastolic BP (Ϸ12 mm Hg reduction) compared to control OA-or vehicletreated animals ( Figure 1B and 1D) , without any apparent changes in the heart rate (Online Figure I) . These results strongly indicate that OA-NO 2 treatment has a significant impact on Ang II-induced hypertension through a prolonged and sustained reduction of BP.
We then monitored BP in isoflurane-anesthetized mice by in vivo tracing recordings on short-term infusion of Ang II, which results in a rapid increase in systemic BP. OA and OA-NO 2 (1 mmol/L, infusion rate: 1 L/min) administered before Ang II delivery (10 g/mL, infusion rate: 1 L/min) did not alter basal BP recordings (Figure 2A and 2B) . Rather, OA-NO 2 , but not similar concentrations of the native OA, significantly prevented BP elevation after short-term infusion of Ang II ( Figure 2C ). To determine whether OA-NO 2 actually reduces the pressor response to Ang II, we then administered OA-NO 2 to mice 3 days after Ang II osmotic minipump implantation ( Figure 2D and 2E). Under these experimental conditions, OA-NO 2 but not OA results in a dose-dependent reduction of BP to the preexisting Ang II-induced hypertension ( Figure 2F ). Taken together, these results demonstrate that OA-NO 2 diminishes the pressor response to Ang II in vivo, regardless of whether the nitroalkene is administered before of after Ang II challenge.
OA-NO 2 Specifically Inhibits Ang II-Induced Vasoconstriction
To determine the specificity of OA-NO 2 effects on Ang II-induced hypertension, we evaluated whether OA-NO 2 may result in changes of vascular contractility. In isolated secondorder rat mesenteric vessels, the presence of OA-NO 2 (2.5 mol/L) resulted in Ϸ50% reduction of Ang II-mediated vasoconstriction at 10 Ϫ7 mol/L (corresponding to Ϸ70% of the contractile response induced by 50 mmol/L KCl), whereas 5 mol/L OA-NO 2 but not OA almost completely abolishes 
OA-NO 2 Reduction of Ang II-Induced Hypertension Is a PPAR␥-Independent Phenomenon
Because (1) OA-NO 2 activates PPAR␥, 14, 25 (2) PPAR␥ activators downregulate AT 1 R in vascular cells, 26, 27 and (3) certain ARBs inhibit AT 1 R through PPAR␥ activity, 28 -30 we assessed whether PPAR␥ activation by OA-NO 2 contributes to the observed reduction of Ang II-induced hypertension in vivo. 28, 29 To this aim, we first monitored BP by tracing recordings on stimulation with Ang II in response to the treatment with the PPAR␥ antagonist GW9662 ( Figure 4 ). Figure 4C ). Further experiments were performed to determine whether PPAR␥ activation by OA-NO 2 affects already established hypertension. To this aim, we compared the BP lowering effect of OA-NO 2 versus rosiglitazone after preincubation with GW9662 in Ang II-induced hypertensive mice as described above. In response to rosiglitazone treatment, BP reduction (Ϸ7mmHg) was efficiently antagonized by GW9662 (Online Figure II) , whereas OA-NO 2 delivery in the presence of GW9662 results in a dose-dependent BP reduction comparable to the lack of the PPAR␥ antagonist (Online Figure III) . Next, we determine the contractile response of mesenteric rings in response to partial inhibition of Ang II-mediated vasoconstriction by OA-NO 2 (2.5 mol/L) after treatment with GW9662 (10 mol/L). As shown in Figure 4D , OA-NO 2 similarly diminished Ang II-dependent vasoconstriction with or without PPAR␥ antagonism by GW9662 treatment. This series of experiments indicate that PPAR␥ activation by OA-NO 2 is not the major mechanism involved in OA-NO 2 antagonism of both Ang II-mediated hypertension and vasoconstriction. 
OA-NO 2 Forms Covalent Adducts With AT 1 R
Nitroalkenes are highly electrophilic and react with cellular nucleophiles via a reversible Michael addition reaction. 6 Thus, we hypothesized that OA-NO 2 could directly modify nucleophilic residues of AT 1 R and impact the propagation of downstream signaling events. A covalent interaction between OA-NO 2 and AT 1 R was revealed by treatment of HEK293 cells overexpressing AT 1 R with OA-NO 2 or OA. Following immunoprecipitation of AT 1 R from cell lysates, a transalkylation reaction of AT 1 R-bound OA-NO 2 permitted the detection and quantification of OA-NO 2 adduction by HPLC-MS/MS (Online Methods). HEK293 cells treated with increasing concentrations of OA-NO 2 revealed significantly increased levels of AT 1 R-adducted OA-NO 2 compared with control cells ( Figure 5A ). OA-NO 2 bound to the AT 1 R, quantified as a ␤-mercaptoethanol (BME) derivative after nucleophilic exchange of OA-NO 2 from the AT 1 R to BME, 13 revealed a Ϸ20-fold increase of adducted OA-NO 2 in AT 1 Rexpressing cells when compared to controls ( Figure 5C ). The MS/MS-induced fragmentation of recovered BME-OA-NO 2 adducts gave product ions and ion intensities similar to a synthetic BME-OA-NO 2 standard and BME-[ 13 C 18 ]-OA-NO 2 used as an internal control ( Figure 5B) . Thus, the presence of BME-exchangeable OA-NO 2 demonstrates the Figure 2 . OA-NO 2 inhibits the pressor response to Ang II. BP was monitored on treatment with OA (A) and OA-NO 2 (B) (10 mg/kg) before Ang II infusion (10 g/mL, infusion rate: 1 L/min). All drugs were delivered via jugular vein administration starting at the time indicated by the arrows. BP tracings were recorded by insertion of a microtip catheter sensor into the right carotid artery. C, Systolic BP was averaged for a 10 minutes period before and after Ang II infusion (10 g/mL, infusion rate: 1 L/min). Data are shown as meansϮSEM (nϭ6 in each group). OA-NO 2 significantly reduced the pressor response to Ang II infusion compared to OA. PϽ0.05 (OA-NO 2 vs OA after Ang II infusion). Hypertension was developed in mice in 3 days after implantation of osmotic pumps to infuse Ang II at a pressor rate of 500 ng/kg per minute. OA (D) or OA-NO 2 (E) were then delivered to mice via the jugular vein at increasing concentrations as indicated by the arrows. BP tracings were recorded as described above. F, Data in D and E are summarized as systolic BP reduction (in mm Hg) after either OA or OA-NO 2 treatment as compared to maximal systolic pressure in Ang II hypertensive mice. OA-NO 2 treatment but not OA dose-dependently reduced established hypertension on Ang II delivery. Data are shown as meansϮSEM (nϭ4 in each group). *PϽ0.05. direct adduction of the AT 1 R by OA-NO 2 . Moreover, immunoprecipitation of AT 1 R from HEK293 cells transfected with Flag-tagged AT 1 R after treatment with biotin-labeled OA-NO 2 , showed a dose-dependent increase in biotin-OA-NO 2 -adducted to the AT 1 R compared with biotin-OA-treated controls ( Figure 5D ). Thus, 2 independent approaches showed that AT 1 R is a relevant cellular target of OA-NO 2 alkylation.
OA-NO 2 Does Not Interfere With Ang II Binding to the Receptor
Next, we sought to determine whether the adduction of the AT 1 R by OA-NO 2 interferes with Ang II binding. Unlike the ARB losartan, that inhibits Ang II binding to AT 1 R, neither OA-NO 2 nor OA affected binding of radio-labeled Ang II to its receptor ( Figure 5E ). Furthermore, neither OA-NO 2 nor OA influenced the displacement of [ 125 I]Ang II bound to AT 1 R in ligand-receptor binding competition analyses using nonradioactive Ang II ( Figure 5F ). This indicates that OA-NO 2 adduction of the AT 1 R does not affect Ang II binding and represents a novel manner of AT 1 R antagonism that is distinct from competitive ARBs. 31 
OA-NO 2 Interferes With G-Protein Coupling to the AT 1 R and Prevents Ang II-Mediated Contractile Responses in Vascular Smooth Muscle Cells
Because OA-NO 2 adduction of the AT 1 R does not affect Ang II binding, we next examined whether OA-NO 2 affects AT 1 R coupling to the heterotrimeric G-protein (G␣ q11 ). To this aim, we treated HEK293 cells overexpressing HA-tagged AT 1 R, G␣ q11 -EGFP, G␤ 1 , and HA-tagged G␥ 2 with OA-NO 2 
Discussion
Early studies deciphering the physiological and/or pharmacological roles of nitrated fatty acids indicate that nitro derivatives of fatty acids exert relevant biological effects in the vasculature [32] [33] [34] (also reviewed 35 ). More recent data, using cardiovascular models of disease, strongly support the notion that nitroalkenes serve as novel therapeutic tools associated with vascular and cardiac tissue damage. 11 In the present study, we provide compelling evidence supporting that OA-NO 2 reduces Ang II-mediated hypertension in a model of Ang II infusion in mice. Systemic delivery of pharmacological doses of OA-NO 2 but not OA resulted in a prolonged and sustained reduction of BP throughout the 14 days of Ang II infusion. The differences in BP in the OA-NO 2 group as compared to OA or vehicle group were more pronounced during the first week of Ang II infusion, when BP raised and remained highest, and persisted significantly lower during the second week of Ang II infusion, when physiological compensatory mechanisms might occur to reduce BP in response to a long-term hypertensive challenge. 36 Thus, our long-term radiotelemetry analysis confirmed that OA-NO 2 diminished the pressor response to Ang II rather than simply delay Ang II-dependent hypertension. Furthermore, comparative analysis with the inclusion of the OA-treated group, as the nonnitrated counterpart for OA-NO 2 also indicates that OA alone at the dosage used in the present study does not reduce Ang II-mediated hypertension in contrast to previous studies indicating that OA or related species might be hypotensive. 37 Thus, at an infusion rate of 5 mg/kg per day, reduction of Ang II-mediated hypertension is afforded by the nitrated but not free form of OA.
Under our experimental conditions, Ang II infusion did not result in significant changes of free nitroalkenes in plasma (data not shown), indicating that chronic infusion of Ang II might not generate sufficient systemic reactions to be detected at the serum level of these hypertensive mice. It has been previously shown that proinflammatory stimuli increases fatty acid nitration in macrophages. 38 In vivo, nitroalkene production is abundantly generated in the mitochondria of the heart after ischemia/reperfusion injury. 12, 13 Therefore, it seems critical to determine the local production of nitroalkenes in response to certain types of injury and on specific subcellular compartments locally in tissues. From the present study, it cannot be excluded that local generation of Figure 5 . OA-NO 2 forms covalent adducts with AT 1 R but does not affect Ang II binding to the receptor. A, HEK293 cells were transfected with 500 ng of FLAG-tagged AT 1 R plasmid (pcDNA3.1-AT 1 R) vs control plasmid (pcDNA3.1) and treated with OA or OA-NO 2 as indicated. Immunoprecipitated AT 1 R was subjected to a BME-based transnitroalkylation reaction 13 as detailed in the Online Data Supplement. Adducted OA-NO 2 to AT 1 R was released as BME-OA-NO 2 and quantified using mass spectrometry. The chromatographic profile shows a dose-dependent increase of OA-NO 2 after immunoprecipitation against AT 1 R and verified by coelution with [ 13 C 18 ]OA-NO 2 internal standard (bottom). B, The fragmentation pattern (top) of AT 1 R-derived OA-NO 2 (5 mol/L treatment) adducted to BME was confirmed by comparison with that of [ 13 C 18 ]OA-NO 2 (bottom). Enhanced levels of the ion products in the peaks and comparison to the internal standard confirmed the structure for the proposed adducts formed after transnitroalkylation. The data shown are a representative set of 3 independent experimental repetitions. C, Quantification of the AT 1 R-derived BME adducts after nucleophilic exchange of OA-NO 2 from the AT 1 R to BME reveals a significant increase of adducted OA-NO 2 to the AT 1 R (270 vs 13 pmol/L BME-OA-NO 2 , respectively, after 5 mol/L OA-NO 2 treatment). nitrated fatty acids, for instance, within the vasculature, might occur in response to Ang II. 39 In ex vivo vasoconstriction assays, OA-NO 2 inhibited Ang II-mediated vascular contractility in an AT 1 R-dependent fashion. Specificity for the AT 1 R relies on the observations that OA-NO 2 dose-dependently inhibited Ang II-mediated vessel contraction but did not reduced vascular contractility induced by vasoconstrictors signaling through other GPCR, such as the observed ET-1 and PE. Activation of PPAR␥ by OA-NO 2 is a well-established mechanism that could account for the reduction of Ang II-induced hypertension and vascular contractility by OA-NO 2 . A reverse relationship between AT 1 R signaling and PPAR␥ has been recognized because genetic polymorphisms in the PPAR␥ locus cause hypertension 40 and PPAR␥ agonists improve hypertension and vascular function. 41 Regardless, whereas pharmacological inhibition of PPAR␥ efficiently blunts rosiglitazone effects on BP, it did not reverse OA-NO 2 reduction of Ang II-mediated hypertension. Moreover, experimental animal models clearly indicate that PPAR␥ regulates vascular contractility mediated not only by AT 1 R but also by other GPCR. 42, 43 Taking into account that OA-NO 2 specifically reduced Ang II-mediated vascular contractility but did not interfere with the contractile properties of ET-1 and PE, it can be concluded that PPAR␥ activation by OA-NO 2 is not the major mechanism involved in OA-NO 2 effects on Ang II-induced hypertension.
Notably, we demonstrate by 2 independent experimental approaches that OA-NO 2 binds to the AT 1 R. Quantitative analysis of the adduction of OA-NO 2 to the AT 1 R was demonstrated by the nucleophilic exchange of nitroalkenes from adducted proteins to BME, as extensively described. 13 The transnitroalkylation reaction of OA-NO 2 from AT 1 R adduction to BME revealed a dose-dependent increase of bound OA-NO 2 to the AT 1 R. These results were further confirmed by immunoprecipitation analysis of AT 1 R and detection of biotinylated OA-NO 2 . However, adduction of the AT 1 R by OA-NO 2 did not interfere with Ang II binding to its receptor, suggesting that the molecular interactions between OA-NO 2 and AT 1 R are unlikely similar to typical competitive inhibitors of AT 1 R. 44, 45 Crystal structures for some proteins of the seven transmembrane family, to which the AT 1 R belongs, show that monomers associate through a lipophilic interface with limited protein-protein contacts. 46 It is becoming increasingly evident that lipid/membrane structures interact with GPCR, exerting posttranslational modification within the GPCR. 47 It is likely that these protein/lipid interactions 48, 49 may serve as regulatory mechanisms with diverse impact on downstream signaling actions. 47 Thus, AT 1 R adduction by OA-NO 2 may result in an allosteric inhibition by adducting to the hydrophobic interface in a fashion reminiscent of the A 2A adenosine receptor antagonist. 50 This could promote an inactive state of the receptor, thus uncoupling Ang II binding from downstream activation. 47 Further studies will be aimed at dissecting the molecular mechanisms by which electrophilic fatty acid derivatives reduce Ang II-mediated hypertension, including biochemical and crystallographic approaches, thus aiding in the design of a new generation of AT 1 R antagonists with increased selectivity.
In summary, this is the first demonstration that OA-NO 2 has a long-lasting impact on hypertension induced by Ang II infusion and exerts a significant BP-lowering effect on Figure 6 . OA-NO 2 uncouples G␣ q11 to the AT 1 R and inhibits Ang II-induced IP 3 production and Ca 2؉ mobilization in VSMC. A, HEK293 cells cultured in 6-well plates were cotransfected with HA-tagged AT 1 R (0.3 g), G␣ q11 -EGFP (0.3 g), G␤ 1 (0.1 g), and G␥ 2 (0.1 g) plasmids and treated with either OA, OA-NO 2 (2.5 mol/ L), or losartan (1 mol/L) 10 minutes before stimulation with Ang II (100 nmol/L) for 1 minute. Immunoprecipitated G␣ q11 using a GFP antibody was subjected to deglycosylation before Western blot analysis for detection of HA-tagged AT 1 R. OA-NO 2 but not OA reduced AT 1 R coupled to the immunoprecipitated G␣ q11. The data shown are representative of 3 independent experiments. B, Western blots were quantified using the ImageJ software after densitometric scanning of the films and expressed as relative ratio of AT 1 R vs G␣ q11 (nϭ3). PϽ0.05, OA-NO 2 vs OA in Ang II-treated cells; PϽ0.05, Ang II-treated vs vehicle control cells (Con). C, VSMCs were treated with either 2.5 mol/L OA-NO 2 or OA and then pulsed with 100 nmol/L Ang II for 45 minutes. IP 3 production was monitored by radioreceptor assays. Ang II induced a 2-fold increase of intracellular IP 3 , whereas OA-NO 2 , but not OA, blocked Ang II-mediated IP 3 production (nϭ6). PϽ0.05, OA-NO 2 vs OA in Ang II-treated cells; PϽ0.05, Ang II-treated vs vehicle control cells (Con). D, VSMCs were similarly treated with either OA-NO 2 or OA (2.5 mol/L) and then pulsed with Ang II (100 nmol/L) in the presence of fura-2. Control experiments were performed with losartanpretreated (1 mol/L) cells. Emission ratio between 340 and 380 nm was used to calculate intracellular calcium concentration as described in Online Data Supplement. The data shown depict a representative time tracing of 6 independent experiments. The ratiotime traces were generated by averaging 3 typical cells in the field of view, as described in Online Figure VI and Online Movies I through III.
preexisting hypertension. OA-NO 2 antagonizes Ang II signaling through formation of stable adducts with the AT 1 R, leading to a reduced vasoconstriction via uncoupling G-protein signaling and subsequently reducing second messenger mobilization.
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